Unknown NA INTERVENTIONAL 2-arm NCT02258282

Safety and Efficacy of Etanercept in Patients With Psoriasis

Sponsor: Chengdu PLA General Hospital

Conditions Psoriasis

Updated 7 times since 2017 Last updated: Mar 31, 2017 Started: May 31, 2014 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02258282, this NA trial focuses on Psoriasis and remains ongoing. Sponsored by Chengdu PLA General Hospital, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status NA

Status: Active Not Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Active Not Recruiting NA
Jun 2018 — Jan 2021 [monthly]

Active Not Recruiting NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting NA

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chengdu PLA General Hospital

Data source: Chengdu PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China